Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

U.S. President Joe Biden and German Chancellor Angela Merkel speak at a press conference

U.S. President Joe Biden and German Chancellor Angela Merkel hold a joint press conference in the East Room of the White House in Washington, D.C. on July 15, 2021. (Photo: Saul Loeb/AFP via Getty Images)

'This Summit Was a Failure': Biden-Merkel Meeting Ends With No Deal on Vaccine Patent Waiver

Biden's inability to persuade Merkel to drop her opposition to the patent waiver "delivers a punishing blow to efforts to end the pandemic," said one critic.

Jake Johnson

The brief bilateral summit between U.S. President Joe Biden and outgoing German Chancellor Angela Merkel ended Thursday without any commitment from the European leader to drop her opposition to a temporary patent waiver for coronavirus vaccines, a result that public health campaigners dubbed a major failure as infections continue to surge across the globe.

"Tens of millions of lives and livelihoods worldwide are left in peril, including here, given that raging Covid outbreaks anywhere increase the chances for a vaccine-resistant strain emerging."
—Lori Wallach, Public Citizen

Lori Wallach, director of Public Citizen's Global Trade Watch, said in a statement that Biden's inability to move Merkel on the patent waiver "delivers a punishing blow to efforts to end the pandemic."

"People around the world dying for lack of vaccines were relying on Biden to get Merkel to stop blocking the waiver given that he promised that if elected president, he wouldn't allow Big Pharma monopolies to block global vaccine and treatment access," said Wallach. "Tens of millions of lives and livelihoods worldwide are left in peril, including here, given that raging Covid outbreaks anywhere increase the chances for a vaccine-resistant strain emerging. We urge the president to redouble his efforts to get the waiver enacted."

While Biden reportedly raised the patent waiver during his private meeting with Merkel on Thursday, it's unclear to what extent he pressed the German leader on the issue—and the president did not mention the proposal during a news conference following their discussion.

Merkel, who was also silent on the patent waiver during the media briefing, said that "we are convinced... that overcoming this pandemic is only possible if as many people as possible are vaccinated in our countries."

"We have to also support the rest of the world with vaccines. We work together with COVAX," the German leader said, referring to the World Health Organization-backed global vaccination initiative that has struggled to meet its goals due to supply shortages.

Experts and public health advocates have argued that the only way to ensure the speedy production and equitable distribution of at least 11 billion vaccine doses—the number believed to be necessary to end the pandemic worldwide—is to temporarily suspend intellectual property protections that are allowing major pharmaceutical companies to maintain a vice grip on vaccine formulas and key technology.

Activists amplified that message outside the White House and across the nation during Merkel's U.S. visit, lining up body bags in the nation's capital to symbolize the preventable deaths caused by the European leader's continued obstruction of the waiver proposal, which India and South Africa first introduced at the World Trade Organization (WTO) back in October.

Proponents argue that a suspension of certain intellectual property protections for the duration of the pandemic would help facilitate the production of generic vaccines, which could then be distributed to low-income nations that have struggled to obtain doses thanks in part to hoarding by wealthy countries.

"As long as Germany withholds its approval of the TRIPS waiver, it threatens the lives of millions of people around the world and our ability to crush the virus."
—Rep. Pramila Jayapal

According to Our World in Data, just 1% of people in low-income countries have received at least one vaccine dose. Haiti—in the midst of a political crisis following the assassination of its president—had yet to administer a single vaccine dose as of Thursday, when 500,000 doses donated by the U.S government through COVAX arrived in the country.

Jean Gough, UNICEF's regional director for Latin America and the Caribbean, said in a statement that "thanks to this donation, hundreds of thousands of Haitians will receive their shots against Covid-19."

"Yet, despite the collective efforts to kickstart the vaccination campaign soon, most of the Haitian population is at risk of remaining unvaccinated due to the limited availability of doses currently in the country," Gough warned.

Biden garnered widespread applause after he voiced support for the temporary patent waiver in May, but the president has since come under fire for not doing enough to convince other world powers—including Germany, Canada, and the United Kingdom—to follow suit. Because the WTO operates by consensus, a handful of rich countries have the power to block a proposal backed by more than 140 countries.

"This summit was a failure," Wallach said Thursday, "and we urge Biden to prioritize getting the WTO waiver enacted ASAP so more Covid vaccines and treatments can be produced worldwide."

With Germany and other rich countries stonewalling the patent waiver, the ultra-contagious Delta variant of the coronavirus is running rampant in undervaccinated regions of the world, including Africa, South America, and pockets of the United States. The World Health Organization said Thursday that Africa reported a million coronavirus cases in just the past month, the fastest surge of new infections on the continent thus far.

"As long as Germany withholds its approval of the TRIPS waiver, it threatens the lives of millions of people around the world and our ability to crush the virus," U.S. Rep. Pramila Jayapal (D-Wash.), chair of the Congressional Progressive Caucus, said in a statement Thursday, referring to the Trade-Related Aspects of Intellectual Property Rights agreement.

"The pandemic isn't over until it's over everywhere," Jayapal added.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

160 Patient Advocates Demand Medicare Negotiation in Build Back Better Package

"We're confident that inclusion of comprehensive drug pricing reforms in the reconciliation package will lower prices, save lives, and ensure continued development of innovative new drugs."

Jessica Corbett ·


'Cartoonish Level Corrupt': As Dems Fight for Bold Agenda, Sinema to Fundraise With Its Corporate Opponents

"Sinema is setting her political future on fire," said one Democratic organizer. "If she doesn't change course drastically and soon, it will be too late."

Brett Wilkins ·


'Momentous Win': Years of Local Opposition Defeats PennEast Pipeline

Opponents in Pennsylvania and New Jersey cheer "cancellation of this unneeded, dangerous fracked gas pipeline."

Jessica Corbett ·


Amid Calls for Closure, House Dems Urge NYC Officials to End 'Inhumane Conditions' at Rikers

A dozen prisoners have died this year alone at the notoriously violent and overcrowded jail complex.

Brett Wilkins ·


'Quite Literally What Instigated the Tunisian Revolution': Outrage After NYC Food Vendor's Stall 'Trashed'

"The abuse of street vendors will continue until there is legislative change, creating a pathway for New York City's smallest businesses to formalize."

Kenny Stancil ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo